January 22, 2016.
Shire (Dublin, Ireland) today announced that it has completed its acquisition of Dyax Corp. (Burlington, MA) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.
Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for hereditary angioedema (HAE), representing a potential additional $646 million in aggregate contingent consideration.
Shire’s Chief Executive Officer, Flemming Ornskov commented: “The addition of Kalbitor and DX-2930 to our portfolio strengthens our leadership position in HAE and, along with the commercial and research and development expertise at Dyax, is a clear strategic fit for us that advances our position as the global leader in rare diseases."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.